Company announce ambulatory blood pressure data for vibegron 75 mg (Gemtesa) in overactive bladder
Post-hoc subgroup analyses from Phase 3 EMPOWUR study (n=214) found no statistically significant or clinically relevant differences in mean daytime and 24-hour ambulatory systolic blood pressure (BP), diastolic BP or heart rate after 28 days of treatment with vibegron vs placebo.
Source:
Biospace Inc.
SPS commentary:
Vibegron is a highly selective oral β3‐adrenoreceptor agonist that does not inhibit the CYP2D6 enzyme pathway and is approved in US for the treatment of adult patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency .
This standalone study was conducted to understand its potential effects on heart rate and blood pressure in a dedicated study using ambulatory blood pressure measurements.